Table 2.

p53 Codon 72 polymorphism genotype distribution in healthy controls (n= 193) and patients with SCCHN (n = 122), n (%)

Arg/ArgPro/ProArg/ProTotal
Controls114 (59)13 (7)66 (34)193
SCCHN*66 (54)1 (1)55 (45)122
Pharynx31 (49)1 (2)31 (49)§63
Other sites35 (59)024 (41)59
  • NOTE: Differences in genotype distribution were evaluated by the χ2 test for independence. The risk for the development of SCCHN in patients harboring heterozygote versus homozygote genotypes was determined by the calculation of OR and 95% CI (genotype distribution in control group served as reference).

  • * χ2 = 8.52, df = 2, P = 0.01.

  • OR, 1.58; 95% CI, 1.0-2.5.

  • χ2 = 5.94, df = 2, P = 0.05.

  • § OR, 1.86; 95% CI, 1.0-3.3.

  • χ2 = 4.51, df = 2, P = 0.10.

  • OR, 1.32; 95% CI, 0.7-2.4.